Affiliations
AffiliationsItem in Clipboard
Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term SurveillanceMarcia Irene Canto et al. Gastroenterology. 2018 Sep.
. 2018 Sep;155(3):740-751.e2. doi: 10.1053/j.gastro.2018.05.035. Epub 2018 May 24. Authors Marcia Irene Canto 1 , Jose Alejandro Almario 2 , Richard D Schulick 3 , Charles J Yeo 4 , Alison Klein 5 , Amanda Blackford 5 , Eun Ji Shin 6 , Abanti Sanyal 7 , Gayane Yenokyan 7 , Anne Marie Lennon 6 , Ihab R Kamel 8 , Elliot K Fishman 8 , Christopher Wolfgang 9 , Matthew Weiss 9 , Ralph H Hruban 10 , Michael Goggins 2 AffiliationsItem in Clipboard
AbstractBackground & aims: Screening of individuals who have a high risk of pancreatic ductal adenocarcinoma (PDAC), because of genetic factors, frequently leads to identification of pancreatic lesions. We investigated the incidence of PDAC and risk factors for neoplastic progression in individuals at high risk for PDAC enrolled in a long-term screening study.
Methods: We analyzed data from 354 individuals at high risk for PDAC (based on genetic factors of family history), enrolled in Cancer of the Pancreas Screening cohort studies at tertiary care academic centers from 1998 through 2014 (median follow-up time, 5.6 years). All subjects were evaluated at study entry (baseline) by endoscopic ultrasonography and underwent surveillance with endoscopic ultrasonography, magnetic resonance imaging, and/or computed tomography. The primary endpoint was the cumulative incidence of PDAC, pancreatic intraepithelial neoplasia grade 3, or intraductal papillary mucinous neoplasm with high-grade dysplasia (HGD) after baseline. We performed multivariate Cox regression and Kaplan-Meier analyses.
Results: During the follow-up period, pancreatic lesions with worrisome features (solid mass, multiple cysts, cyst size > 3 cm, thickened/enhancing walls, mural nodule, dilated main pancreatic duct > 5 mm, or abrupt change in duct caliber) or rapid cyst growth (>4 mm/year) were detected in 68 patients (19%). Overall, 24 of 354 patients (7%) had neoplastic progression (14 PDACs and 10 HGDs) over a 16-year period; the rate of progression was 1.6%/year, and 93% had detectable lesions with worrisome features before diagnosis of the PDAC or HGD. Nine of the 10 PDACs detected during routine surveillance were resectable; a significantly higher proportion of patients with resectable PDACs survived 3 years (85%) compared with the 4 subjects with symptomatic, unresectable PDACs (25%), which developed outside surveillance (log rank P < .0001). Neoplastic progression occurred at a median age of 67 years; the median time from baseline screening until PDAC diagnosis was 4.8 years (interquartile range, 1.6-6.9 years).
Conclusions: In a long-term (16-year) follow-up study of individuals at high-risk for PDAC, we found most PDACs detected during surveillance (9/10) to be resectable, and 85% of these patients survived for 3 years. We identified radiologic features associated with neoplastic progression.
Keywords: Early Detection; Familial Pancreatic Cancer; IPMN; PanIN-3.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.
Conflict of interest statementDisclosures: MG, APK and RHH have received royalties for the licensing of PALB2 as a pancreatic cancer susceptibility gene. All other authors have no relevant financial, personal, or professional conflicts.
FiguresFigure 1
Cumulative risk (hazard) for neoplastic…
Figure 1
Cumulative risk (hazard) for neoplastic progression (PDAC, IPMN-HGD, or PanIN-3) for high risk…
Figure 1Cumulative risk (hazard) for neoplastic progression (PDAC, IPMN-HGD, or PanIN-3) for high risk individuals after baseline screening. Overall neoplastic progression rate was 1.6% per year.
Figure 2
Risk for neoplastic progression was…
Figure 2
Risk for neoplastic progression was significantly increased in HRI with worrisome features (radiologic…
Figure 2Risk for neoplastic progression was significantly increased in HRI with worrisome features (radiologic progression) (p < 0.0001) (2A) and those beginning screening at age > 60 (2B).
Figure 2
Risk for neoplastic progression was…
Figure 2
Risk for neoplastic progression was significantly increased in HRI with worrisome features (radiologic…
Figure 2Risk for neoplastic progression was significantly increased in HRI with worrisome features (radiologic progression) (p < 0.0001) (2A) and those beginning screening at age > 60 (2B).
Figure 3
Incident asymptomatic 7 mm pancreatic…
Figure 3
Incident asymptomatic 7 mm pancreatic cancer detected after 10 years of surveillance, shown…
Figure 3Incident asymptomatic 7 mm pancreatic cancer detected after 10 years of surveillance, shown by arrows in endoscopic ultrasound (EUS) image (A) and gross pathology section of the pancreatic body (B). Final pathologic diagnosis was stage T1N0 moderately differentiated adenocarcinoma with negative margins (cytology smear from EUS-guided fine needle aspiration) C; hematoxylin and eosin stain, venous and perineural invasion were not identified (D).
Figure 4
Kaplan-Meier curves for overall survival…
Figure 4
Kaplan-Meier curves for overall survival for high risk individuals diagnosed with pancreatic neoplasms…
Figure 4Kaplan-Meier curves for overall survival for high risk individuals diagnosed with pancreatic neoplasms diagnosed by surgery or endoscopic ultrasound guided fine needle aspiration. The group “Others” includes pathologically-proven lower grade pancreatic neoplasms that were not PDAC, IPMN-HGD, or PanIN-3 (IPMN with LGD or MGD, PanIN-2, PanNET, serous cystadenoma, pseudocyst).
Similar articlesKamata K, Kitano M, Kudo M, Sakamoto H, Kadosaka K, Miyata T, Imai H, Maekawa K, Chikugo T, Kumano M, Hyodo T, Murakami T, Chiba Y, Takeyama Y. Kamata K, et al. Endoscopy. 2014 Jan;46(1):22-9. doi: 10.1055/s-0033-1353603. Epub 2013 Nov 11. Endoscopy. 2014. PMID: 24218310
Konings ICAW, Canto MI, Almario JA, Harinck F, Saxena P, Lucas AL, Kastrinos F, Whitcomb DC, Brand RE, Lachter J, Malleo G, Paiella S, Syngal S, Saltzman JR, Stoffel EM, van Hooft JE, Hruban RH, Poley JW, Fockens P, Goggins MG, Bruno MJ; International CAncer of the Pancreas Screening (CAPS) Consortium. Konings ICAW, et al. BJS Open. 2019 Jul 2;3(5):656-665. doi: 10.1002/bjs5.50180. eCollection 2019 Oct. BJS Open. 2019. PMID: 31592073 Free PMC article.
Sawai Y, Yamao K, Bhatia V, Chiba T, Mizuno N, Sawaki A, Takahashi K, Tajika M, Shimizu Y, Yatabe Y, Yanagisawa A. Sawai Y, et al. Endoscopy. 2010 Dec;42(12):1077-84. doi: 10.1055/s-0030-1255971. Epub 2010 Nov 30. Endoscopy. 2010. PMID: 21120776
Tanaka M. Tanaka M. Digestion. 2014;90(4):265-72. doi: 10.1159/000370111. Epub 2015 Jan 10. Digestion. 2014. PMID: 25591885 Review.
Smith LA, McKay CJ. Smith LA, et al. Minerva Med. 2016 Dec;107(6):370-380. Epub 2016 Sep 14. Minerva Med. 2016. PMID: 27627636 Review.
Chen Q, Cherry DR, Nalawade V, Qiao EM, Kumar A, Lowy AM, Simpson DR, Murphy JD. Chen Q, et al. JCO Clin Cancer Inform. 2021 Mar;5:279-287. doi: 10.1200/CCI.20.00137. JCO Clin Cancer Inform. 2021. PMID: 33739856 Free PMC article.
Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, Bassi C, Carrato A, Farrell J, Fishman EK, Fockens P, Gress TM, van Hooft JE, Hruban RH, Kastrinos F, Klein A, Lennon AM, Lucas A, Park W, Rustgi A, Simeone D, Stoffel E, Vasen HFA, Cahen DL, Canto MI, Bruno M; International Cancer of the Pancreas Screening (CAPS) consortium. Goggins M, et al. Gut. 2020 Jan;69(1):7-17. doi: 10.1136/gutjnl-2019-319352. Epub 2019 Oct 31. Gut. 2020. PMID: 31672839 Free PMC article.
Walker EJ, Goldberg D, Gordon KM, Pedley C, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH, Blanco AM, Dhawan M. Walker EJ, et al. Oncologist. 2021 Nov;26(11):e1982-e1991. doi: 10.1002/onco.13968. Epub 2021 Sep 20. Oncologist. 2021. PMID: 34506673 Free PMC article.
Katona BW, Long JM, Ahmad NA, Attalla S, Bradbury AR, Carpenter EL, Clark DF, Constantino G, Das KK, Domchek SM, Dudzik C, Ebrahimzadeh J, Ginsberg GG, Heiman J, Kochman ML, Maxwell KN, McKenna DB, Powers J, Shah PD, Wangensteen KJ, Rustgi AK. Katona BW, et al. Cancer Prev Res (Phila). 2021 Nov;14(11):1033-1040. doi: 10.1158/1940-6207.CAPR-21-0161. Epub 2021 Aug 2. Cancer Prev Res (Phila). 2021. PMID: 34341011 Free PMC article.
Bartsch DK, Matthäi E, Mintziras I, Bauer C, Figiel J, Sina-Boemers M, Gress TM, Langer P, Slater EP. Bartsch DK, et al. Dtsch Arztebl Int. 2021 Mar 12;118(10):163-8. doi: 10.3238/arztebl.m2021.0004. Dtsch Arztebl Int. 2021. PMID: 33531114 Free PMC article.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.3